Clinical Trials Logo

Pancreas Cancer clinical trials

View clinical trials related to Pancreas Cancer.

Filter by:
  • Recruiting  
  • « Prev · Page 14

NCT ID: NCT01411072 Recruiting - Pancreas Cancer Clinical Trials

Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer

Start date: September 2011
Phase: N/A
Study type: Interventional

Chemotherapy is given after curative surgery for pancreas cancer to try to improve cure rates. There are two choices of chemotherapy which are currently considered equal treatments: gemcitabine or 5-fluorouracil (5FU). This study is trying to determine if one of two standard chemotherapies is better than the other depending on whether patients have high or low human equilibrative nucleoside transporter 1 (hENT1). hENT1 is a protein that is found in varying amounts on pancreas cancers.

NCT ID: NCT00809081 Recruiting - Pancreas Cancer Clinical Trials

Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy

Start date: July 2007
Phase: Phase 3
Study type: Interventional

Pancreaticoduodenectomy is associated with a high incidence of postoperative complications. These postoperative complications could delay postoperative resumption of adequate oral intake. Clinical study on postoperative feeding after pancreaticoduodenectomy is very limited. Method of Nutritional support (Enteral feeding or total parenteral support)after pancreaticoduodenectomy is controversial. 1. To evaluate whether early enteral nutrition may be a suitable alternative to total parenteral nutrition 2. To evaluate whether enteral feeding improve nutritional status after pancreaticoduodenectomy

NCT ID: NCT00259532 Recruiting - Pancreas Cancer Clinical Trials

Three New Methods for Diagnosing Pancreas Cancer

Start date: February 2005
Phase: N/A
Study type: Interventional

The purpose of this project is to evaluate and compare three new methods for diagnosis, staging, operability evaluation and treatment control of pancreas cancer. The investigators use contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas. The hormones induce an increased metabolism and thus an increased blood flow through healthy pancreas tissue, however, not in tumor tissue. The investigators hope to be able to use this effect diagnostically. The patients included will also have a 64-slice-CT in order to evaluate, if an increased diagnostic safety can be reached compared to an older CT scanning method. All patients will also be examined for the tumor marker CA 19-9. Further, the investigators will examine if contrast-enhanced ultrasound can contribute with information in treatment control after either surgery or medical treatment.